Eyepoint Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.9
- Today's High:
- $11.98
- Open Price:
- $11.65
- 52W Low:
- $2.19
- 52W High:
- $11.44
- Prev. Close:
- $11.65
- Volume:
- 433920
Company Statistics
- Market Cap.:
- $205.13 million
- Book Value:
- 2.285
- Revenue TTM:
- $39.79 million
- Operating Margin TTM:
- -206.59%
- Gross Profit TTM:
- $26.95 million
- Profit Margin:
- -257.44%
- Return on Assets TTM:
- -25.75%
- Return on Equity TTM:
- -83.56%
Company Profile
Eyepoint Pharmaceuticals Inc had its IPO on 2005-01-27 under the ticker symbol EYPT.
The company operates in the Healthcare sector and Biotechnology industry. Eyepoint Pharmaceuticals Inc has a staff strength of 144 employees.
Stock update
Shares of Eyepoint Pharmaceuticals Inc opened at $11.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.9 - $11.98, and closed at $11.27.
This is a -3.26% slip from the previous day's closing price.
A total volume of 433,920 shares were traded at the close of the day’s session.
In the last one week, shares of Eyepoint Pharmaceuticals Inc have increased by +7.13%.
Eyepoint Pharmaceuticals Inc's Key Ratios
Eyepoint Pharmaceuticals Inc has a market cap of $205.13 million, indicating a price to book ratio of 0.7274 and a price to sales ratio of 2.1535.
In the last 12-months Eyepoint Pharmaceuticals Inc’s revenue was $39.79 million with a gross profit of $26.95 million and an EBITDA of $-80353000. The EBITDA ratio measures Eyepoint Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eyepoint Pharmaceuticals Inc’s operating margin was -206.59% while its return on assets stood at -25.75% with a return of equity of -83.56%.
In Q1, Eyepoint Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.3%.
Eyepoint Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.71 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eyepoint Pharmaceuticals Inc’s profitability.
Eyepoint Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.1117 and a EV to EBITDA ratio of 0.1622. Its price to sales ratio in the trailing 12-months stood at 2.1535.
Eyepoint Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $154.59 million
- Total Liabilities
- $27.24 million
- Operating Cash Flow
- $32.09 million
- Capital Expenditure
- $484000
- Dividend Payout Ratio
- 0%
Eyepoint Pharmaceuticals Inc ended 2024 with $154.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $154.59 million while shareholder equity stood at $78.39 million.
Eyepoint Pharmaceuticals Inc ended 2024 with $13.27 million in deferred long-term liabilities, $27.24 million in other current liabilities, 770062000.00 in common stock, $-692515000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $105.77 million and cash and short-term investments were $122.48 million. The company’s total short-term debt was $5,295,000 while long-term debt stood at $29.37 million.
Eyepoint Pharmaceuticals Inc’s total current assets stands at $146.06 million while long-term investments were $0 and short-term investments were $16.72 million. Its net receivables were $10.42 million compared to accounts payable of $9.45 million and inventory worth $4.07 million.
In 2024, Eyepoint Pharmaceuticals Inc's operating cash flow was $32.09 million while its capital expenditure stood at $484000.
Comparatively, Eyepoint Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $11.27
- 52-Week High
- $11.44
- 52-Week Low
- $2.19
- Analyst Target Price
- $32.14
Eyepoint Pharmaceuticals Inc stock is currently trading at $11.27 per share. It touched a 52-week high of $11.44 and a 52-week low of $11.44. Analysts tracking the stock have a 12-month average target price of $32.14.
Its 50-day moving average was $11.48 and 200-day moving average was $6.26 The short ratio stood at 2.08 indicating a short percent outstanding of 0%.
Around 1057.5% of the company’s stock are held by insiders while 8603.6% are held by institutions.
Frequently Asked Questions About Eyepoint Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company’s pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.